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Protocol
AbstrACt
Introduction Dementia is the fastest growing major cause 
of disability globally with a mounting social and financial 
impact for patients and their families but also to health and 
social care systems. This review aims to systematically 
synthesise evidence on the utilisation of resources and 
costs incurred by patients and their caregivers and by 
health and social care services across the full spectrum 
of dementia, from its preceding preclinical stage to end of 
life. The main drivers of resources used and costs will also 
be identified.
Methods and analysis A systematic literature review 
was conducted in MEDLINE, EMBASE, CDSR, CENTRAL, 
DARE, EconLit, CEA Registry, TRIP, NHS EED, SCI, RePEc 
and OpenGrey between January 2000 and beginning of 
May 2017. Two reviewers will independently assess each 
study for inclusion and disagreements will be resolved by 
a third reviewer. Data will be extracted using a predefined 
data extraction form following best practice. Study quality 
will be assessed with the Effective Public Health Practice 
Project quality assessment tool. The reporting of costing 
methodology will be assessed using the British Medical 
Journal checklist. A narrative synthesis of all studies will 
be presented for resources used and costs incurred, by 
level of disease severity when available. If feasible, the 
data will be synthesised using appropriate statistical 
techniques.
Ethics and dissemination Included articles will be 
reviewed for an ethics statement. The findings of the 
review will be disseminated in a related peer-reviewed 
journal and presented at conferences. They will also 
contribute to the work developed in the Real World 
Outcomes across the Alzheimer’s disease spectrum for 
better care: multi-modal data access platform (ROADMAP).
trial registration number CRD42017071413.
IntroduCtIon
Dementia is the fastest growing major cause 
of disability globally.1 According to the World 
Alzheimer Report 2016, over 47 million 
people live with dementia worldwide. This 
number is predicted to almost double every 
20 years with over 130 million expected to live 
with the condition by 20502. The human and 
financial burden associated with this disease 
is vast: the global cost was estimated to be 
US$818 billion in 2015, equivalent to more 
than the Gross Domestic Product (GDP) of 
countries such as Switzerland and the Neth-
erlands.3 Dementia is predicted to become a 
trillion dollar disease by 20184. It therefore 
represents a very relevant challenge from 
both a medical and economic perspective.
Dementia is a debilitating condition for 
which there is no cure. It is a progressive 
neurodegenerative syndrome characterised 
by cognitive, behavioural and neuropsychi-
atric changes which impair social function 
and activities of daily living (ADLs). Alzhei-
mer’s disease (AD) is the most common cause 
of dementia, accounting for one half to three 
quarters of all cases.5 Other forms of dementia 
include vascular dementia, dementia with 
Lewy bodies and frontotemporal dementia 
among others. There is increasing recogni-
tion of co-occurrence of different forms of 
dementia—especially vascular pathologies 
alongside AD. What all the diseases share in 
common is an inevitable decline in cognition, 
such that patients are in need of extensive 
strengths and limitations of this study
 ► This systematic literature review on resource use 
and costs of dementia was based on a detailed 
search strategy.
 ► Search strategy did not specify countries of interest 
or limit languages.
 ► The review follows robust guidelines and the quality 
of the papers included will be assessed using a 
validated tool.
 ► The heterogeneity in the reported measures of 
resource use and costs may not enable direct 
comparisons between studies to be made.
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personal care, including supervision and assistance with 
ADLs.
The financial cost of dementia is vast and continually 
growing but remains difficult to quantify. In the last 
decade, a few reviews have analysed the cost of illness 
data in dementia, with the last update conducted in 
2013.6–8 These have highlighted the significant direct 
non-medical costs associated with care, primarily 
informal care costs and costs of formal services both 
home-based and in care homes in addition to the direct 
medical costs. These reviews have also drawn attention 
to the indirect costs which arise from the effect on 
families, carers and the community. These are more 
challenging to measure and there is significant varia-
tion in the methodology used to estimate these costs. 
Many of these recent reviews were limited to studies 
addressing AD alone and they did not include studies 
reported in languages other than English. Furthermore, 
these reviews did not quantify the costs associated with 
predementia states including preclinical AD (biomarker 
positive but presymptomatic), early symptoms, mild 
cognitive impairment (MCI) or prodromal AD. Given 
the constantly increasing number of dementia patients, 
further investigation is warranted to analyse the factors 
which are driving the soaring costs. This review aims to 
address the following questions:
i. What type and level of resources are used by patients 
with dementia in all stages of dementia disease se-
verity, from preclinical to end of life, and their 
caregivers?
ii. What are the direct, indirect and informal costs of 
these patients and caregivers?
iii. Are resource use and costs significantly associated 
with specific factors?
MEthods And AnAlysIs
Protocol and registration
This protocol was prepared according to the reporting 
guidelines of the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis for Protocols 2015 (PRIS-
MA-P)9 and the completed PRISMA-P checklist can be 
found in the online supplementary file 1. The review 
protocol was registered with the PROSPERO interna-
tional prospective register of systematic reviews (registra-
tion number CRD42017071413). The systematic review 
manuscript will be prepared following the PRISMA state-
ment.10–12 Important amendments to this protocol will be 
reported and published with the results of the review.
study selection criteria
Participants
Studies will be included if the full or part of the study popu-
lation is reported to have either preclinical (presymp-
tomatic) AD; early symptoms; MCI; prodromal AD; mild, 
moderate or severe dementia or is a caregiver of a person 
with predementia or dementia, irrespective of the type 
and stage of the disease. However, only studies focusing 
on adult populations will be considered for inclusion.
Study design
This systematic review will include studies published in 
peer-reviewed journals or gray literature, where outcomes 
were estimated based on patient-level data. In terms of 
study design, both interventional and observational 
studies will be considered for inclusion (regardless of 
whether a prospective or retrospective approach is used) 
as well as register-based studies. Where multiple studies 
used the same patient cohort, data extraction will be 
restricted to the study that presented the most detailed 
information on resources used and costs for dementia. 
Furthermore, case studies, series of case studies, studies 
with sample size of <30 patients, trial protocols, phase I 
clinical trial, news articles, interviews (that do not use a 
structured quantitative questionnaire), patient educa-
tion handouts, reviews, opinion or expert articles, edito-
rial, letters to the editor, authors and editor’s replies to 
comments will not be included.
Modelling studies will be excluded but studies 
informing the model parameters will be considered for 
inclusion. Similarly, reviews of existing economic studies 
on dementia will not be included but their reference 
lists will be screened for additional studies. Conference 
abstracts will be screened in order to determine whether 
the work presented had been published in a peer-re-
viewed journal or gray literature. However, the abstracts 
themselves will not be considered for inclusion.
Outcomes
The outcomes of interest are as follows:
 ► The resources used by patients and their caregivers.
 ► The costs incurred by patients and their caregivers.
Where possible, both resources used and costs incurred 
will be detailed by stage of the disease: preclinical AD 
(biomarker positive but presymptomatic), early symp-
toms (memory and other behavioural changes), MCI, 
prodromal AD, mild dementia, moderate dementia, 
severe dementia and end of life in order to understand 
how costs evolve throughout disease progression. Data 
on any further subdivision of stage of disease will also be 
extracted if described in studies.
Where studies present multiple data points, all relevant 
data points will be individually extracted and kept sepa-
rate for analysis. For example, data will be individually 
extracted from studies that present data from multiple 
time points, studies that present data from multiple coun-
tries and studies that present data from multiple settings 
(eg, community and institutionalised).
The costs will be presented as annual costs incurred 
per patient, and will be linearly extrapolated or interpo-
lated if necessary. Costs will be extracted in local currency. 
However, if the cost estimates are not reported in local 
currency, these will be converted to local currency using 
the annual reported currency exchange rates for the year 
of costing. All cost estimates will be inflated to the last 
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available year with deflator data for all countries included 
in the review, using the World Bank GDP deflator for 
each country.13 Inflated costs will be converted to USD 
using the GDP Purchasing Power Parity conversion rates 
for each country.14
Intervention
All dementia-related interventions, either symptomatic or 
disease modifying, will be included. We will also consider 
studies that have not assessed any intervention.
Language
No language restrictions were applied to the search.
Setting
No geography or clinical setting restrictions were applied 
to the search.
search strategy
Electronic databases
Electronic databases were selected in conjunction with 
an information specialist. The search terms were devel-
oped based on previous literature reviews’ search strat-
egies15 with the assistance of the information specialist. 
The following electronic databases were searched from 
1 January 2000 to 4 May 2017: Medical Literature Anal-
ysis and Retrieval System Online (MEDLINE), Excerpta 
Medica dataBASE (EMBASE), Cochrane Database 
of Systematic Reviews (CDSR), Central Register of 
Controlled Trials (CENTRAL), Database of Abstracts of 
Reviews of Effects (DARE), EconLit, Cost-Effectiveness 
Analysis Registry (CEA Registry), Turning Research Into 
Practice (TRIP), NHS Economic Evaluation Database 
(NHS EED), Science Citation Index (SCI), Research 
Papers in Economics (RePEc) and OpenGrey Repository 
(OpenGrey). The exact search terms used in all databases 
are described in the online supplementary file 2. The 
database searches have now been completed.
Manual searches
The reference list of the studies included in this review, 
as well as those of previous literature reviews on resources 
used and costs across the full spectrum of dementia, will 
be searched in order to identify additional potentially 
relevant studies. The studies informing the model param-
eters in identified modelling studies will be considered 
for inclusion. Conference abstracts identified through 
the electronic searches will be screened and manuscripts 
of relevant abstracts will be manually searched for.
Study selection
The references will be managed in ENDNOTE X7, 
Thomson Reuters. The removal of duplicates in terms 
of title and first author name will be performed by one 
reviewer. Afterwards, two reviewers will independently 
assess the titles and abstract of the studies to determine 
whether full text review is needed. Disagreement between 
the two reviewers will be resolved by a third reviewer. Full 
text of potentially eligible studies will be retrieved and 
reviewed and assessed for final inclusion by two reviewers 
with a third reviewer being consulted in case of disagree-
ment. Non-English references will be screened by native 
or fluent speaker identified from a pool of collaborators 
at the University of Oxford. A flow diagram will be created 
to illustrate the selection process according to PRISMA 
guidelines.10
Data extraction
Data will be independently extracted by two of following 
reviewers (EN, ERD, FL, IG, HW, RH, SM) using a 
data extraction form (online supplementary file 3) 
with disagreements being solved by the third reviewer. 
Non-English references will be reviewed by two native 
or fluent speakers. The following information will be 
extracted:
 ► Study details: title, author, publication details, loca-
tion, language of the study, countries of the study.
 ► Study design: aim of the study, type of study, type of 
analysis, duration, outcomes measured, instruments 
used to measure them.
 ► Participant information: type of participant, setting, 
inclusion and exclusion criteria, sample size, sociode-
mographic information.
 ► Disease specific information: type of dementia, level of 
severity, instrument used to measure level of severity.
 ► Outcomes: outcomes measured, subgroup analysis 
conducted, adjustments carried out.
 ► Results: resources used by patients or their caregivers 
by disease severity, costs incurred by patients or their 
caregivers by disease severity, type of costs, costing 
methodology, cost perspective.
 ► Conclusions: authors’ conclusions.
Risk of bias (quality) assessment
A quality assessment of each study will be independently 
conducted by two of following reviewers (EN, ERD, FL, 
IG, HW, RH, SM) using the Effective Public Health Prac-
tice Project ‘Quality assessment tool for quantitative 
studies’16 recommended by the Cochrane Public Health 
Group as it covers a wide range of study designs.17
A quality assessment for the reporting of the costing 
methodology will also be undertaken using a shortened 
version18 of the British Medical Journal Checklist to assess 
the quality of economic evaluations19 (online supplemen-
tary file 4).
The quality assessment of non-English studies will be 
carried out by two native or fluent speakers.
Description of studies and analysis
We expect to find a diverse range of study designs and 
heterogeneous presentations of resources used and costs. 
Data will be presented in terms of annual cost per patient, 
as detailed above. Costs will be presented separately, 
when possible, for the different types of dementia, but 
with a special emphasis on AD, the most common form 
of dementia. If possible, cost data will be presented for 
each stage of the disease. Costs will also be subdivided 
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by cost category: direct (medical and non-medical) costs, 
indirect costs and informal costs.20 21
A narrative synthesis of all relevant studies will be 
provided discussing differences in resources used and 
costs incurred by type of dementia, disease severity, type of 
cost, cost perspective, study design, and describing study 
and participants’ characteristics, results and author’s 
conclusions.
The authors of the studies included in this review will 
be contacted with the aim to retrieve any missing data 
necessary for our analysis.
dIsCussIon
This systematic review will synthesise the resources used 
and costs incurred by patients across the full spectrum of 
dementia from predementia through dementia to end of 
life. The resources used and costs incurred by their care-
givers will also be summarised. Detailing the consump-
tion of resources and associated costs throughout the 
different stages of the disease can contribute to a better 
understanding of the economic impact of dementia and 
also better inform disease progression and cost-effective-
ness models, especially when in some cases costs were 
reported to be more than double between later stages of 
the disease.22
Even though our main interest is AD, given the lack of 
diagnostic accuracy and the recognised overlap between 
different causes of dementia, all forms of dementia will be 
considered and the costs will be presented separately by 
disease type, if the information is available.
The quality of the studies included in this review will be 
assessed and, if feasible, the resource use and cost data 
will be synthesised using appropriate statistical methods. 
Furthermore, this review will include studies conducted 
in the last 17 years without any languages or geographic 
restrictions in contrast to previous reviews which were 
restricted to studies published in English language up to 
2013. The review was limited to studies published in or 
after the year 2000 to ensure that the results of the review 
were applicable to present settings. Only one previous 
review6 assessed the quality of the studies.
In conclusion, this review aims to address the economic 
impact of dementia, globally recognised as a health 
priority not only in terms of the impact it has on older 
people’s health but also on health and social care systems 
worldwide. Understanding the economic implications of 
this disease will allow policy-makers to devise better health 
and social care plans for both patients with dementia and 
their caregivers.
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